Expression analysis of centrin gene in promastigote and amastigote forms of Leishmania infantum iranian isolates: a promising target for live attenuated vaccine development against canine leishmaniasis

Mohammad Javad Abbaszadeh Afshar1, Samira Elikaee1,2, Reza Saberi3, Sina Mohtasebi1 and Mehdi Mohebali1,4*

Abstract

Background: Leishmania parasites express various essential proteins in different growth phases (logarithmic/stationary) and forms (promastigote/amastigote). Targeting the genes encoding such proteins paves the way for controlling these parasites. Centrin is an essential gene, which its protein product seems to be vital for the proliferation of Leishmania parasites. Herein, this study was contrived to analyze the expression level of the centrin gene in different growth phases and forms of Leishmania infantum (L. infantum) parasites isolated from various endemic areas of canine leishmaniasis (CanL) in Iran.

Results: All three collected isolates were identified as L. infantum using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Real-time reverse transcription (RT)-PCR revealed a statistically significant up-regulation (3.13-fold) in the logarithmic phase promastigotes compared to stationary ones \(p < 0.01\), whereas centrin was expressed equally in intracellular amastigotes at different time points during cell culture. Also, our finding revealed a slight up-regulation of the centrin gene (1.22-fold) in the intracellular amastigotes compared to logarithmic phase promastigotes, which was found statistically non-significant \(p > 0.05\).

Conclusions: Centrin gene in Iranian isolates of L. infantum is more expressed in exponential than stationary phases and seems to be considered as a promising target in the development of a genetically modified live attenuated vaccine for CanL control.

Keywords: Centrin gene, Leishmania infantum, Canine leishmaniasis, Gene expression, Real-time RT-PCR

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Canine leishmaniasis (CanL) caused by Leishmania infantum (L. infantum), as a challenging global zoonosis, is endemic in some areas in Iran and 70 countries around the world [1–3]. The parasite is transmitted accidentally from the infected dogs, as the main reservoir of CanL, to humans through sandflies biting and cause visceral leishmaniasis (VL), the most severe clinical form of leishmaniasis. However, the number of new symptomatic human VL cases reported annually is around 100 cases in Iran, reviewing the conducted studies on domestic dogs indicates the disease is prevalent at least in half of the country’s provinces [4, 5]. Therefore the formation of the new VL foci is not far-fetched in Iran.

Vaccination is the most cost-effective control strategy for controlling CanL, in that successful immunization of dogs could interrupt transmission and reduce the incidence of VL significantly [6]. Several approaches for vaccine development against CanL have been evaluated such as killed parasites, live attenuated parasites, recombinant proteins, and naked DNA [6]. Unlike other approaches, live attenuated vaccines lead to interactions with the host immune system resulting in a wide range of antigens similar to natural parasite infection, hence could provide more protection [7]. Development of live attenuated Leishmania parasites, including long-term in vitro cultures, chemical mutagenesis, and irradiation, is associated with some problems like undefined random genetic mutations or potential reversion virulence. While, genetically modified live attenuated vaccines, through targeting the genes encoding essential proteins like growth-regulating or virulence genes, are safe [8]. To target such genes, it would be essential to analyze their function in different forms and growing phases of Leishmania parasites.

Various qualitative and quantitative biochemical parameters affect the differentiation, proliferation, pathogenesis, and survival of Leishmania parasites, which are different in each form and growing phase of the parasite [9–11]. For instance, the genes related to infectivity are up-regulated in metacyclic promastigotes [11]. Amastigotes also change their gene expression levels to survive and multiply in the hostile environment inside the macrophage’s phagolysosomes. Some of these modifications in gene expression levels may point to unique parasite genes that could be targeted to the development of a prophylactic vaccine [12, 13].

Several studies have characterized genes that may have an essential role in the growth and proliferation of the Leishmania parasite [10, 14]. Centrin gene and its function concerning the Leishmania parasite proliferation have been described as one of the mentioned genes [15]. Centrin gene product is one of the several regulatory proteins required for duplication or segregation of the centrosome in higher eukaryotes and basal bodies in lower eukaryotes [16]. The role of centrin in cytokinesis of yeast and HeLa cells and also the formation of flagellate in Chlamydomonas has been documented in several studies [17–20]. Also, centrin is described as one of the essential factors in cell division of several protozoa such as Leishmania, Trypanosoma, and Plasmodium [15, 21, 22].

To target centrin for developing a genetically modified live attenuated vaccine against CanL in Iran, it would be essential to analyze its expression in the different forms and growing phases of L. infantum parasites. Hence, this study aimed to compare the expression level of the centrin gene in the logarithmic phase compared to the stationary phase of L. infantum promastigotes and also the comparison of the expression level of the centrin gene in the promastigote and amastigote forms of L. infantum Iranian isolates using real-time reverse transcription (RT)-PCR.

Results
Molecular characterization
All three Leishmania isolates collected from various endemic areas of Iran were identified as L. infantum using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Following the N-acetylglucosamine-1-phosphate transferase (NAGT) gene digestion with the Acetyl-coenzyme A carboxylase 1 (Acc1) enzyme, all isolates exhibited three bands (780, 500, and 180 bp) on the agarose gel, which corresponds to L. infantum (Fig. 1).

Complementary DNA (cDNA) synthesis and real-time RT-PCR analysis
The integrity of synthesized cDNA was determined by conventional PCR through α-tubulin amplification as a housekeeping gene. Real-time RT-PCR was used to compare the relative expression of the centrin gene in the logarithmic and stationary phase promastigotes and also in the logarithmic promastigote and amastigote forms of L. infantum isolates. Figure 2 shows significant up-regulation of the centrin gene in the logarithmic phase compared to stationary phase L. infantum promastigotes in all three collected isolates. The overall average mRNA expression of the centrin gene in the logarithmic phase promastigotes was 3.13-fold of its expression in stationary phase ones (p < 0.01).

The results of the current study also showed centrin expressed equally in the intracellular amastigotes at different time points (24 h and 72 h post-infection) during the cell culture (data not shown). Also, our results revealed a slight up-regulation of the centrin gene (1.22-fold) in the intracellular amastigotes compared to logarithmic phase promastigotes, which was found statistically non-significant (p > 0.05) (Fig. 3). Moreover, we
investigated the centrin gene expression level among each *L. infantum* isolate, in which there was no significant difference (*p > 0.05*).

**Discussion**

Centrin gene product is a cytoskeletal, calcium-binding protein located at the basal body region of *Leishmania* parasites. The nature of the basal body and the genes associated with this vital unit in *Leishmania* parasites are still poorly known. Centrin protein, besides calmodulin, γ-tubulin, and other types of centrin, is an essential regulatory protein required for duplicating the basal body in *Leishmania* parasites [15]. To investigate the expression pattern of the centrin gene in different growth phases (logarithmic/stationary) and forms (promastigote/
amastigote) of *L. infantum*, isolated from various endemic areas of Iran, we conducted a real-time RT-PCR. As our results revealed, the centrin gene expression pattern had no significant difference in *L. infantum* isolates of various geographical areas of Iran. Our findings showed a significant up-regulation of the centrin mRNA expression in the logarithmic phase compared to the stationary phase of *L. infantum* promastigotes in all three collected isolates. The overexpression of this protein in logarithmic phase *L. infantum* parasites confirms the finding of the study carried out on *Leishmania donovani* (*L. donovani*) parasites [23]. Based on the mentioned study, *Leishmania* centrin protein expression was high during the exponential growth phase of the parasite in culture and significantly declined in the stationary phase. This expression pattern suggests that *Leishmania centrin* may have an essential role in the proliferation of the parasite. Furthermore, since stationary promastigotes compare to logarithmic ones are highly motile [24], the specified expression pattern in the current study indicates centrin protein may not have a role in the cellular movement.

Regarding the centrin gene expression level in the logarithmic phase *L. infantum* promastigote and amastigotes, although no significant overexpression was found, the results of this study revealed that the mRNA of *L. infantum* centrin gene is slightly more expressed in amastigotes than logarithmic promastigotes. This finding is somewhat consistent with the results of Selvapandiy et al. [23], where they report centrin protein is equally expressed in the promastigote and amastigote forms of *L. donovani*. The results of the mentioned study have shown a defect in cell division among amastigote forms of *L. donovani centrin* gene knockout (*LdCen<sup>−/−</sup>*) while promastigote forms of *LdCen<sup>−/−</sup>* proliferate without any defect. It seems other types of proteins, such as calmodulin, γ-tubulin, and other types of centrin proteins, are responsible for basal body duplication in the promastigote forms. The lack of significant difference in the centrin expression between non-motile amastigote and promastigote forms confirms the fact that centrin has no role in parasite movement.

*Leishmania* parasites, especially the zoonotic species, have a complex transmission dynamics that is dependent on environmental conditions, the distribution and biology of the vector, the reservoirs involved, and the health, social, and economic aspects that affect the human host [25]. The strategies and interventions for the control of VL, including control of vectors and reservoirs and the early detection and treatment of human cases, faced some economic and moral limitations [26]. The mentioned complex scenario for the transmission dynamics of *L. infantum*, on the other hand, makes it even more difficult to establish effective control measures and highlights the need for the development of an effective prophylactic vaccine against CanL [27].

Our findings, besides the results obtained by Selvapandiy et al. [15, 23], showed a significant dependence of the *Leishmania* parasite’s amastigote forms on the centrin gene activity. *Centrin* is a single copy gene [15], and its protein product as one of the main proteins required for duplication of the basal body and cell division could be an appropriate target for the prevention of *L. infantum* amastigotes proliferation in host cells. Defects in basal body duplication and cytokinesis in the *L. infantum* amastigote stage seem to be an attractive way to reach a genetically modified live attenuated vaccine against CanL.
In this study, because of financial constraints, we just collected three *L. infantum* isolates from various endemic areas of Iran. Indeed, by evaluating more isolates, a more precise picture of the *centrin* expression profile could be achieved.

**Conclusions**

Analysis of the *centrin* gene expression in Iranian isolates of *L. infantum* showed this gene is more expressed in exponential than stationary phases, which highlights the potential role of *centrin* in the proliferation of these parasites. Understanding the role of *centrin* in *L. infantum* proliferation is a cornerstone to alter the survival of the parasite in the vertebrate host and could be a promising clue to the development of a genetically modified live attenuated vaccine against CanL.

**Methods**

**Isolates and culture**

We used three *Leishmania* parasites isolated from domestic dogs in endemic areas of CanL in Iran. The parasites were grown in RPMI 1640 (Gibco, Germany) culture medium supplemented with 20% heat-inactivated fetal bovine serum (FBS) (Gibco, Germany), plus penicillin (100 U/ml) and streptomycin (100 µg/ ml) (Sigma, USA), at pH 7.4 and incubation temperature of 25°C [28].

**Molecular characterization**

**DNA extraction**

We harvested 2 mL well-grown promastigotes by centrifugation (800 g, 5 min at 4°C) and washed twice using sterile phosphate-buffered saline (PBS). Total DNA was extracted from the parasites using AccuPrep® Genomic DNA Extraction Kit (Bioneer, Korea) according to the manufacturer’s instructions and stored at -20°C until the subsequent process.

**PCR-RFLP**

PCR-RFLP was performed using the NAGT gene, which amplified using the primer set, forward (5'-TCTAGGACT CTGCGCTGTTA-3') and reverse (5'-CTCTAGCC CACTTCATCGTAG-3') [29] which amplifies a fragment of approximately 1450-60 base-pair (bp) in *Leishmania* parasites (Fig. 2 Lane 2). We carried out the PCR amplification in a final reaction mixture containing 25 µL including 12.5 µL 2x red PCR Master Mix (Ampliqon, Denmark), 1 µL of each primer (10 pmol), 1 µL of the extracted DNA and 9.5 µL of sterile distilled water. We applied a negative control in each run. PCR was performed in the thermal cycler (PeqLab, Germany) using the following cycling protocol: an initial denaturation step at 94°C for 4 min, followed by 30 cycles of denaturation at 94°C for 1 min, annealing at 53°C for 1 min and extension at 72°C for 1 min, followed by a final extension step at 72°C for 8 min.

Species identification was carried out using RFLP analysis. Acc1 enzyme (Thermo Scientific, USA) can provide different digestion patterns in different *Leishmania* species. For this purpose, we added 10 µL of the ampli-con, 2 µL of the enzyme buffer, 1 µL of the Acc1 enzyme and 17 µL distilled water to the reaction. The mixture was incubated at 37°C for 12 h and then visualized on 2% agarose gel [29].

We used pre-confirmed *L. infantum*, *Leishmania major*, and *Leishmania tropica* species by PCR-RFLP [30], available at the School of Public Health, Tehran University of Medical Sciences as positive controls (Fig. 1 Lane 3–5, respectively).

**Centrin gene expression**

**Cell culture and amastigote isolation**

Mouse macrophage cell line RAW264.7 (ATCC number TIB-71) was obtained from the Iranian Biological Resource Center, Tehran, Iran. The macrophage cells were cultured in RPMI 1640 medium supplemented with 20% heat-inactivated FBS, penicillin (100 U/mL), and streptomycin (100 µg/mL) at 37°C in a humidified atmosphere of 5% CO₂ in 25 cm² culture flasks (SPL, Korea). Following 72 h incubation (60 to 70% confluency), we washed unattached macrophages off using the pre-warmed medium and incubated attached ones with the late stationary phase promastigotes (10 *Leishmania* per macrophage), as described by Mohtasebi et al. [31]. The culture was incubated in the same medium supplemented at 37°C for 4 to 6 h in the same condition until promastigotes were phagocyte by the macrophages. Then uninternalized parasites were washed off using pre-warmed medium.

Intracellular amastigotes were harvested and extracted from macrophages at 24 h and 72 h post-infection using a protocol as described by Decuyper et al. [32] with minor modifications. Briefly, 2 mL of 0.0125% sodium dodecyl sulfate (SDS)/PBS were added to the culture flask and gently agitated until macrophages lifted and started to disintegrate. After mixing, the contents of the culture flask were aspirated through a 22-gauge needle, causing further shearing of the macrophages, and transferred to a 50 mL tube for differential centrifugation as follows; a 30 g centrifugation to separate the macrophages and a 700 g centrifugation to obtain the amastigote pellet.

**RNA extraction and cDNA synthesis**

Total RNA was obtained from the 5 × 10⁶ logarithmic and stationary phase promastigotes (96 h and 192 h post-subculture, respectively) and also from the 5 × 10⁶ axenic amastigotes at 24 h and 72 h post-infection of
three *L. infantum* isolates, using FavorPrep™ Total RNA Extraction Mini Kit (Favorgen, Taiwan), following the manufacturer’s instructions. We performed an agarose gel electrophoresis to assess the overall quality of total RNA. The quantity of total RNA was also estimated using NanoDrop™ One/OneC Microvolume UV-Vis Spectrophotometer (Thermo Scientific, USA). Samples having an A_{260}/A_{280} ratio of between 1.8 and 2.0 were considered. To avoid any genomic DNA contamination, we treated the extracted RNA using DNase (Qiagen, Germany) following the manufacturer’s recommendations. Total RNA was reverse transcribed from 1 µg of total RNA using the cDNA Synthesis Kit (YTA, Iran) according to the manufacturer’s instructions. Afterward, we evaluated the integrity of the synthesized cDNA through amplification of the *a-tubulin* as a housekeeping gene using primer set, forward (5’-CAGGTGGTGT CGTCTCTGAC-3’) and reverse (5’-TAGTCGTCA GCACGAAGTG-3’), under the condition as described previously [28]. The PCR result was considered positive when a single band of 119 bp was observed.

**Real-time RT-PCR**

We conducted a real-time RT-PCR assay to analyze the expression level of the *centrin* gene. *Centrin* primers were obtained using the Primer-BLAST tool [33] including forward (5’-CCGCTCTATGCAACACAGACT-3’) and reverse (5’-AGGTCAAGAGCTGAAAGGC-3’) which amplifies a 126 bp fragment in the experiments. The housekeeping gene, *a-tubulin*, was used as endogenous control and run along with the gene tested. RT-PCR was performed in duplicate with 20 µL volumes containing 10 µL RealQ Plus 2x Master Mix Green (Ampliqon, Denmark), 1 µL cDNA, 1 µL of each primer (10 pmol), and 7 µL distilled water in a StepOne™ Real-time PCR System (Applied Biosystems, USA). The PCR condition was as follows: initial denaturation at 95°C for 30 sec, 40 cycles of 10 sec at 95°C and 30 sec at 60°C followed by a melt curve analysis using temperature increments of 0.3°C every 30 sec to ascertain amplification of the expected product. A negative control, consisting of nontemplate water instead of cDNA, was used in each run of real-time RT-PCR.

**Data analysis**

The relative expression of the *centrin* gene in the *L. infantum* isolates was estimated and normalized to the internal control gene (*a-tubulin*) using the 2^–ΔΔCt method [34]. The significance of differences was determined by the relative expression software tool (REST, ). All experiments conducted in duplicate and the obtained results have presented as the mean ± standard deviations. The expression ratio results of the target gene were tested for significance by a Pair Wise Fixed Reallocation Randomization Test® and plotted using standard error estimation via a complex Taylor algorithm, calculated by REST. The samples with a *p*-value of < 0.05 were considered significantly different among the groups [35].

**Abbreviations**

Canl: Canine leishmaniasis; VL: Visceral leishmaniasis; PCR: Polymerase chain reaction; bp: Base-pair; RFLP: Restriction fragment length polymorphism; DNase: Deoxyribonuclease; RT: Reverse transcription; SDS: Sodium dodecyl sulfate; PBS: Phosphate-buffered saline; FBS: Fetal bovine serum; NAGT: N-acetylglucosamine-1-phosphate transferase; Acct1: Acetyl-coenzyme A carboxylase 1; cDNA: Complementary DNA; *LdCen*−/−: Leishmania donovani centrin gene knockout; mRNA: Messenger RNA; BLAST: Basic local alignment search tool; REST: Relative expression software tool

**Acknowledgements**

We thank Dr. Elham Kazemi-Rad for her insightful suggestions during cell culture and molecular procedures.

**Authors’ contributions**

MJAA, SE, and MM designed the study. MJAA writing the original draft. MJAA and RS carried out molecular procedures and data analysis, and SM participated in the cell culture procedure. All authors read and approved the final version of the manuscript.

**Funding**

This study, as a part of the PhD thesis of Mr. Mohammad Javad Abbaszadeh Afshar, was financially supported by Tehran University of Medical Sciences (Project No: 97-03-160-39686). The funding body did not play a direct role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

**Availability of data and materials**

The datasets generated and analyzed during the current study may be made available from the corresponding author on request.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 2 School of Pharmacy, Pacific University, Hillboro, Oregon, USA. 3 Department of Medical Parasitology and Mycology, School of Medicine, Mazandaran University of Medical Sciences, Mazandaran, Iran. 4 Center for Research of Endemic Parasites of Iran (CREPI), Tehran University of Medical Sciences, Tehran, Iran.

Received: 19 July 2020 Accepted: 23 February 2021

**Published online:** 14 April 2021

**References**

1. World Health Organization. Leishmaniasis. [https://www.who.int/leishmaniasis/burden/en/]

2. Martins VT, Duarte MC, Chávez-Fumagalli MA, Menezes-Souza D, Coelho CS, de Magalhães-Soares DF, Fernandes AP, Soto M, Tavares CA, Coelho EA. A *Leishmania*-specific hypothetical protein expressed in both promastigote and amastigote stages of *Leishmania infantum* employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis. Parasit Vectors. 2015;8(1):1–12.

3. Abbaszadeh-Afshar MJ, Mohebali M, Sharifi I, Akhoundi B, Aflatoonian MR, Bahreini MS, Mahmoudvand H. Seroepidemiological survey of visceral leishmaniasis among nomadic tribes of Kerman province, southeastern Iran: An observational study for implication to health policy. J Biostat Epidemiol. 2015;1(3/4):105–11.
4. Shokri A, Falkh M, Teshnizi SH. Canine visceral leishmaniasis in Iran: A systematic review and meta-analysis. Acta trop. 2017;165:76–89.
5. Abbassadze-Afshar MJ, Sharifi I, Baromravat M, Mohebali M, Bahreini MS, Naderi A. Canine visceral leishmaniasis: A seroepidemiological survey in Jiroft district, southern Kerman province, southeastern Iran in 2015. Iran J Parasitol. 2018;13(1):67–71.
6. Moreno J, Alvar J. Canine leishmaniasis: epidemiological risk and the experimental model. Trends parasitol. 2002;18(9):399–405.
7. Ismail N, Kaul A, Bhattacharya P, Gannavaram S, Nakhasi HL. Immunization with live attenuated Leishmania donovani centrin+ parasites is efficacious in asymptomatic infection. Front Immunol. 2017;8:1788.
8. Selvapandian A, Dey R, Nylen S, Duncan R, Sacks D, Nakhasi HL. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis. J Immunol. 2009;183(3):1813–20.
9. Bifeld E, Clos J. The genetics of Leishmania virulence. Med Microbiol Immunol. 2015;204(6):619–34.
10. Joshi M, Dwyer DM, Nakhasi HL. Cloning and characterization of differentially expressed genes from in vitro-grown ‘amastigotes’ of Leishmania donovani. Mol Biochem parasitol. 1995;80(2):345–54.
11. Alcolea PJ, Alonso A, Deegayon MA, Moreno-Paz M, Jimenez M, Molina R, Larraga V. In vitro infectivity and differential gene expression of Leishmania infantum metacyclic promastigotes: negative selection with peanut agglutinin in culture versus isolation from the stromodeal valve of Phlebotomus perniciosus. BMC Genomics. 2016;17:375.
12. Dey R, Meneses C, Nakhasi HL, Duncan R. Characterization of a Leishmania stage-specific mitochondrial membrane protein that enhances the activity of cytochrome c oxidase and its role in virulence. Mol Microbiol. 2010;77(2):399–414.
13. Grimaldi G Jr, Teva A, Dos-Santos CB, Santos FN, Pinto ID, Leite GR, Falqueto A. Field trial of efficacy of the Leish-tec® vaccine against canine leishmaniasis caused by Leishmania infantum in an endemic area with high transmission rates. PLoS one. 2017;12(9):e0185438.
14. Pogue KP, Koul S, Lee NS, Dwyer DM, Nakhasi HL. Identification of intra- and interspecific Leishmania genetic polymorphisms by arbitrary primed polymerase chain reactions and use of polymorphic DNA to identify differentially regulated genes. J Parasitol Res. 1995;81(6):282–90.
15. Selvapandian A, Duncan R, Debrabant A, Benholot S, Sreenivas G, Negi NS, Salota P, Nakhasi HL. Expression of a mutant form of Leishmania donovani centrin reduces the growth of the parasite. J Biol Chem. 2001;276(46):43253–61.
16. Ichinose CM, Seghier BM, Paschke T, Spang A, Grein K, Steinkötter J, Melkonian M, Schiebel E. Characterization of green alga, yeast, and human centrins: specific subdomain features determine functional diversity. J Biol Chem. 1996;271(37):22453–61.
17. Baum P, Furlong C, Byers B, Yeast gene required for organelle segregation and cytokinesis in Trypanosoma brucei. Mol Biol Cell. 2007;18(9):3290–301.
18. Paslett A, Bordei N, Haddad R, Schwartz CL, Chang F, Bornens M. Fission yeast split1p is a component of the half-ciridal and controls SPB duplication. Mol Biol Cell. 2003;14(7):2793–808.
19. Selvapandian A, Debrabant A, Bertholet S, Sreenivas G, Negi NS, Salota P, Nakhasi HL. Cloning and characterization of a Leishmania donovani centrin required for organelle segregation and cytokinesis in Trypanosoma brucei. Mol Biol Cell. 2007;18(9):3290–301.
20. Salome I, Monz-Vaziri V, Hajarjan H, Niyati M, Taghipour N, Kheirandish F, Abadi A. Identification of Leishmania species using N-acetylglucosamine-1-phosphate transferase gene in a zoonotic cutaneous leishmaniasis focus of Iran. J Vector Borne Dis. 2018;55(1):14.
21. Teimouri A, Mohebali M, Kazemifard E, Hajarian N. Molecular identification of agents of human cutaneous leishmaniasis and canine visceral leishmaniasis in different areas of Iran using internal transcribed spacer 1 PCR-RFLP. J Anthropol Res. 2018;7(2):162.
22. Yarizadeh H, Darabi M. Reduced genetic diversity of Leishmania donovani in Jiroft district, southern Kerman province, southeastern Iran in 2015. Iran J Parasitol. 2018;13(1):67–71.
23. Abbaszadeh Afshar et al. BMC Veterinary Research (2021) 17:162
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions